A Multicenter, Observational, Open-Label, Single-Arm Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
The purpose of this study is to find out if there are any assessments that might predict whether or not patients receiving Tysabri will remain free of disease and how effective Tysabri is at keeping patient who are in the early stages of RRMS free of disease.
Keywordstysabri, relapsing, multiple sclerosis, anti-jcv, negative
Principal InvestigatorScott Silliman, AST PROFESSOR
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.